PCI Biotech Holding ASA (LTS:0JGL) EBIT : kr-30.35 Mil (TTM As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA EBIT?

PCI Biotech Holding ASA's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was kr-6.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was kr-30.35 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PCI Biotech Holding ASA's annualized ROC % for the quarter that ended in Jun. 2023 was -470.17%. PCI Biotech Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1,400.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PCI Biotech Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -90.79%.

PCI Biotech Holding ASA EBIT Historical Data

The historical data trend for PCI Biotech Holding ASA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA EBIT Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-88.24

-71.84

-88.30

-54.97

-20.16

PCI Biotech Holding ASA Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															-10.61	-7.51	-5.91	-6.33	-

Competitive Comparison of PCI Biotech Holding ASA's EBIT

For the Biotechnology subindustry, PCI Biotech Holding ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's EV-to-EBIT falls into.

PCI Biotech Holding ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-30.35 Mil.

PCI Biotech Holding ASA (LTS:0JGL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PCI Biotech Holding ASA's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-25.3 * ( 1 - 0% )	/	( (6.249	+	4.513)	/ 2 )
=	-25.3	/	5.381
=	-470.17 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	57.615	-	0.245	-	( 51.121	-	max(0, 5.166	-	56.982	+	51.121	))
=	6.249

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	52.518	-	2.427	-	( 45.578	-	max(0, 5.366	-	51.978	+	45.578	))
=	4.513

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PCI Biotech Holding ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-25.3	/	( ( (0.633 + max(1.078, 0))	+	(0.54 + max(1.361, 0)) )	/	2 )
=	-25.3	/	( ( 1.711	+	1.901 )	/	2 )
=	-25.3	/	1.806
=	-1,400.89 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5.861	+	0	+	0)	-	(0.245	+	0	+	4.538)
=	1.078

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.4	+	0	+	0)	-	(2.427	+	0	+	2.612)
=	1.361

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PCI Biotech Holding ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-30.349	/	33.427
	=	-90.79 %

PCI Biotech Holding ASA EBIT Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA (LTS:0JGL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (LTS:0JGL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (LTS:0JGL) Headlines

No Headlines